What is wrong with the design of the Novavax stock options award given to its CEO and three other executives? a) The stock options award brought unnecessary scrutiny from the SEC and the FDA. b) The stock options award enriched the four executives with so much wealth that three of them left the firm before clinical trials were completed. c) Despite the eventual failure of the vaccine, the four executives still earn more than $80 million from their combined stock options. d) The four executives could have earned more than $100 million just by completing a mid-stage milestone, regardless of the vaccine candidate's eventual success